Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine
- Development stage
- Preclinical
- Lead developer
- Collaborations Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine is a small molecule non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Collaborations Pharmaceuticals for the treatment of HIV-1. This compound belongs to a novel class of 1-sulfonyl-3-amino-1H-1,2,4-triazoles specifically designed to address HIV-associated neurocognitive disorders (HAND) by optimizing brain penetration and minimizing neurotoxicity. The lead candidate in this class, compound 12126065, has demonstrated potent picomolar antiviral activity against wild-type HIV-1 and maintains efficacy against clinically relevant NNRTI-resistant mutant strains. Preclinical studies indicate that the molecule possesses a favorable safety profile with no acute or subacute toxicity and excellent central nervous system penetration.
- Other names
- N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine.